Scarica l'app Stockscreener
2.72
1.09%
-0.03
Precedente Chiudi:
$2.75
Aprire:
$2.78
Volume 24 ore:
1.83M
Relative Volume:
0.91
Capitalizzazione di mercato:
$265.41M
Reddito:
$35.95M
Utile/perdita netta:
$-104.99M
Rapporto P/E:
-2.0049
EPS:
-1.3567
Flusso di cassa netto:
$-99.30M
1 W Prestazione:
-10.53%
1M Prestazione:
+43.92%
6M Prestazione:
+2.26%
1 anno Prestazione:
+34.65%
Intervallo 1D:
$2.71
$2.94
Intervallo di 1 settimana:
$2.71
$3.82
Portata 52W:
$1.085
$3.82
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Nome
C 4 Therapeutics Inc
Settore
Industria
Telefono
(617) 231-0700
Indirizzo
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.72 | 265.41M | 35.95M | -104.99M | -99.30M | -1.3567 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Iniziato | TD Cowen | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-15 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2024-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Equal-Weight |
| 2024-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-04-28 | Iniziato | Credit Suisse | Underperform |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-10 | Iniziato | JP Morgan | Overweight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-11-23 | Iniziato | BofA Securities | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-27 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-27 | Iniziato | Jefferies | Buy |
Mostra tutto
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab - Yahoo Finance
Are you looking for a top momentum pick? Why C4 Therapeutics, Inc. (CCCC) is a great choice - MSN
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact (NASDAQ:CCCC) - Seeking Alpha
C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data - Finviz
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Bitget
C4 Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. to join Barclays global healthcare conference fireside chat - Traders Union
Why C4 Therapeutics Inc. stock is popular among millennials2026 Trading Volume Trends & Fast Moving Stock Trade Plans - Naître et grandir
C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference - MarketBeat
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRISPR firm Intellia hands 16,500 RSUs to six new hires - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Bitget
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
C4 Therapeutics : Our Corporate Presentation (d54f12) - marketscreener.com
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
CCCC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
C4 Therapeutics (NASDAQ:CCCC) Upgraded to Hold at Wall Street Zen - MarketBeat
C4 Therapeutics (CCCC) Quarterly Loss Narrows To US$20.5m Challenging Persistent Bearish Narratives - simplywall.st
Barclays Raises Price Target on C4 Therapeutics (CCCC) to $7.00 - GuruFocus
Barclays raises C4 Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Barclays Maintains Overweight on C4 Therapeutics (CCCC) Feb 26, 2026 - Meyka
C4 Therapeutics (NASDAQ:CCCC) Issues Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Barclays raises C4 Therapeutics stock price target on trial progress - Investing.com
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Investing News Network
C4 Therapeutics, Inc. SEC 10-K Report - TradingView
C4 Therapeutics (CCCC) outlines TPD pipeline, losses and major partnerships - Stock Titan
C4 Therapeutics, Inc. posts fourth quarter and full year 2025 financial results - Traders Union
C4 Therapeutics (Nasdaq: CCCC) details 2025 loss and cash runway to 2028 - Stock Titan
C4 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
C4 Therapeutics (CCCC) Price Target Increased by 14.49% to 11.51 - Nasdaq
C 4 Therapeutics Inc Azioni (CCCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):